Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

February 15, 2017

Primary Completion Date

January 8, 2021

Study Completion Date

March 30, 2023

Conditions
EGFR Gene Mutation
Interventions
DRUG

YH25448

"* Dose Escalation: YH25448 20mg\~320mg, PO~* Dose Expansion: YH25448 40mg\~240mg, PO~* Dose Extension: Recommended Dose 240mg of YH25448"

Trial Locations (16)

13496

CHA Bundang Medical Center, CHA University, Seongnam-si

13620

Seoul National University Bundang Hospital, Seongnam-si

14647

The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon-si

16247

The Catholic University of Korea, St. Vincent's Hospital, Suwon

21565

Gachon University Gil Medical Center, Incheon

28644

Chungbuk National University Hospital, Cheongju-si

44033

Ulsan University Hospital, Ulsan

48108

Inje University Haeundae Paik Hospital, Busan

52727

Gyeongsang National University Hospital, Jinju

03080

National Cancer Center, Goyang-si

Seoul National University Hospital, Seoul

03181

Kangbuk Samsung Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

07061

SMG-SNU Boramae Medical Center, Seoul

Unknown

Severance Hospital, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT03046992 - Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC | Biotech Hunter | Biotech Hunter